sb 202190 has been researched along with Basophilic Leukemia, Acute in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaves-Dias, C | 1 |
| Hundley, TR | 1 |
| Gilfillan, AM | 1 |
| Kirshenbaum, AS | 1 |
| Cunha-Melo, JR | 1 |
| Metcalfe, DD | 1 |
| Beaven, MA | 1 |
1 other study available for sb 202190 and Basophilic Leukemia, Acute
| Article | Year |
|---|---|
Induction of telomerase activity during development of human mast cells from peripheral blood CD34+ cells: comparisons with tumor mast-cell lines.
Topics: Acetamides; Androstadienes; Animals; Antigens, CD34; CD13 Antigens; Cell Cycle; Cell Differentiation | 2001 |